Experimentica Ltd. Appoints New Director of In Vivo Pharmacology
Kuopio, Finland, October 22, 2016 --(PR.com)-- Experimentica Ltd., a global ophthalmic contract research organization (CRO) today announced the appointment of Tamuna Bolkvadze, Ph.D. to Director In Vivo Pharmacology, effective immediately.
Dr. Bolkvadze joined Experimentica Ltd. earlier in 2016 as Research Scientist and has been instrumental in growing the company’s In Vivo Division. Dr. Bolkvadze is an accomplished neuroscientist with more than 20 peer-reviewed publications in fields of traumatic brain injury and epileptogenesis.
“Tamuna’s extensive experience in in vivo pharmacology and hands-on expertise in coordinating large-scale in vivo studies will be critical for Experimentica Ltd., as we continue to refine our already industry-leading portfolio of ocular in vivo models,” said Dr. Simon Kaja, Experimentica’s Chief Scientific Officer.
Dr. Giedrius Kalesnykas, CEO of Experimentica Ltd., praised Dr. Bolkvadze’s leadership: “Tamuna has shown the leadership and expertise needed to streamline our In Vivo operations. Her contribution to the Management Team will be instrumental in Experimentica’s ongoing expansion to become the leading CRO for preclinical ocular models.”
About Experimentica Ltd.
Experimentica Ltd. is a preclinical contract research organization (CRO) dedicated to develop and provide ocular disease models. Relying entirely on in-house expertise, Experimentica Ltd. pursues Scientific Excellence in Ocular ModelsSM.
Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland and Chicago, IL, USA. For more information, visit www.experimentica.com.
Media enquiries:
Giedrius Kalesnykas, Ph.D., Chief Executive Officer
Phone: +358 50 379-0275
US Toll Free: +1 (844) 393-4393
Email: info@experimentica.com
Dr. Bolkvadze joined Experimentica Ltd. earlier in 2016 as Research Scientist and has been instrumental in growing the company’s In Vivo Division. Dr. Bolkvadze is an accomplished neuroscientist with more than 20 peer-reviewed publications in fields of traumatic brain injury and epileptogenesis.
“Tamuna’s extensive experience in in vivo pharmacology and hands-on expertise in coordinating large-scale in vivo studies will be critical for Experimentica Ltd., as we continue to refine our already industry-leading portfolio of ocular in vivo models,” said Dr. Simon Kaja, Experimentica’s Chief Scientific Officer.
Dr. Giedrius Kalesnykas, CEO of Experimentica Ltd., praised Dr. Bolkvadze’s leadership: “Tamuna has shown the leadership and expertise needed to streamline our In Vivo operations. Her contribution to the Management Team will be instrumental in Experimentica’s ongoing expansion to become the leading CRO for preclinical ocular models.”
About Experimentica Ltd.
Experimentica Ltd. is a preclinical contract research organization (CRO) dedicated to develop and provide ocular disease models. Relying entirely on in-house expertise, Experimentica Ltd. pursues Scientific Excellence in Ocular ModelsSM.
Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland and Chicago, IL, USA. For more information, visit www.experimentica.com.
Media enquiries:
Giedrius Kalesnykas, Ph.D., Chief Executive Officer
Phone: +358 50 379-0275
US Toll Free: +1 (844) 393-4393
Email: info@experimentica.com
Contact
Experimentica Ltd
Dr. Giedrius Kalesnykas
+358503790275
www.experimentica.com
Dr. Giedrius Kalesnykas
+358503790275
www.experimentica.com
Contact
Categories